The webinar will feature presentations by Key Opinion Leaders (KOLs) Jose-Alain Sahel, M.D. (University of Pittsburgh School of Medicine) and Botond Roska, M.D., Ph.D. (Institute of Molecular and Clinical Ophthalmology Basel) who will discuss The Nature Medicine Case Report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP), in which the subject is a participant in the ongoing PIONEER Phase I/II clinical trial of GenSight Biologics’ GS030 optogenetic therapy. The video of the interview of this patient can be viewed below.
Drs. Sahel and Roska will be available to answer questions following the formal presentations.
Gensight’s management team will also discuss the highlights from the Nature Medicine Case Report and give an update on their pipeline candidate, GS030. Administered via intravitreal injection, GS030 uses an optimized viral vector (GS030-DP) to express the light-sensitive opsin ChrimsonR in retinal ganglion cells and proprietary light-stimulating goggles (GS030-MD) to project the right wavelength and intensity of light onto the treated retina.
Interview of a patient treated with GS030
You are required to register in advance for the webcast. Please click here.
For those who are unable to listen at this time, a replay of the call will be available by clicking here.
If you would like to ask a question during the live Q&A, please submit your request via email firstname.lastname@example.org
- José-Alain Sahel, M.D.
Jose-Alain Sahel, M.D. is Distinguished Professor and Chairman, Department of Ophthalmology, University of Pittsburgh School of Medicine (UPMC); the Eye and Ear Foundation Endowed Chair of Ophthalmology and Director of the UPMC Eye Center; Professor at the Sorbonne University, Paris, France; and Director of the Institut Hospitalo-Universitaire (IHU) FOReSIGHT.
Dr. Sahel is recognized worldwide for his expertise in vision restoration techniques. He has developed a range of interventions for vision impairments that are currently without treatments, such as retinitis pigmentosa, and over the past decade has led pioneering efforts in optogenetic vision restoration. Dr. Sahel is a co-inventor on more than 40 patents, several of which have led to start-up companies. He is a scientific co-founder of several companies, including GenSight Biologics; is an elected member of several scientific societies; and serves on 11 editorial boards. He is the recipient of numerous honours and awards.
- Botond Roska, M.D., Ph.D.
Prof. Botond Roska is one of the founding directors of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) in Switzerland. He is also Professor at the Faculty of Medicine and at the Faculty of Science at the University of Basel.
His research has advanced the understanding of neuronal circuits in the retina, thalamus and cortex; his research group pioneered the use of optogenetic therapy to restore vision to the blind. Prof. Roska has received several prestigious honours and awards, including the Körber European Science Prize and the Louis-Jeantet Prize for Medicine. He has authored over 83 articles and reviews in peer-reviewed journals and serves on multiple scientific advisory and editorial boards.